Promedior's Fibrosis Program Featured at Keystone Symposia Conference

MALVERN, Pa.--(BUSINESS WIRE)--Jan 22, 2009 - Promedior, Inc. today announced that its novel fibrosis program and lead product, PRM-151, recombinant human Serum Amyloid P, are the subject of several presentations and posters this week at the Keystone Symposia conference on Fibrosis in Keystone, Colorado.

“Promedior has developed a novel platform with tremendous potential for the treatment of fibrotic diseases and has rapidly advanced its first product candidate, PRM-151, into position to begin clinical development in 2009,” said Dominick Colangelo, Chief Executive Officer of Promedior. “Promedior is well positioned to become a leader in the development of innovative therapies for the treatment of fibrotic diseases and we are very pleased that our fibrosis program and lead product candidate are prominently featured at this prestigious conference involving leading fibrosis experts from around the world.”

PRM-151, recombinant human Serum Amyloid P (rhSAP), is a highly conserved natural human protein that targets the specific cell populations that orchestrate fibrosis and tissue remodeling. PRM-151 has demonstrated robust preclinical efficacy in all organ systems and tissues and an outstanding safety profile. Seven papers covering mechanism of action and preclinical efficacy studies conducted at leading institutions such as Harvard University, Yale University, and the University of Michigan will be presented at this year's Keystone Symposia conference on Fibrosis.

“PRM-151 has consistently generated impressive preclinical efficacy data in studies involving multiple models of fibrotic disease by multiple investigators from leading institutions around the world,” commented Dr. Tim Pelura, the company's Chief Scientific Officer. “Promedior and its collaborators have shown that the novel mechanistic approach underlying rhSAP biology has many dominant advantages over the often studied cytokine or growth factor approach, which suffers from inherent biological redundancy.”

“Progressive fibrosis is a particularly insidious disease robbing patients of their quality of life and in many cases their lives,” said Professor Cory Hogaboam of the University of Michigan. “Any organ of the body is susceptible to fibrosis, often without warning, and current therapies do little to halt the onset and neutralize the environmental instigators of fibrosis. With the emergence of highly encouraging preclinical data involving PRM- 151, it is becoming apparent that this therapeutic agent uniquely fills both of these voids and holds real promise for fibrosis patients and their families.”

About Promedior, Inc.

Promedior is a product-focused biopharmaceutical company developing novel therapeutics for the treatment of fibrotic disorders and diseases. Fibrosis is a key component of multiple diseases affecting all organ systems and tissues and is a leading cause of morbidity and mortality for millions of people worldwide. Promedior has developed a novel platform to treat fibrotic diseases which focuses on targeting the specific cell populations that orchestrate fibrosis and tissue remodeling. This new paradigm for treating fibrotic diseases is upstream and dominant to traditional approaches and takes advantage of universal biology common to all tissues to promote healing without scarring. Promedior's lead product, PRM-151, recombinant human Serum Amyloid P (rhSAP), is a highly conserved natural human protein that operates at the crossroads between innate immunity, inflammation, and matrix deposition. PRM-151 has demonstrated an outstanding safety profile and robust preclinical efficacy in all organ systems and tissues and all widely-accepted disease models. Promedior expects to begin clinical development of PRM-151 in 2009.

With a leadership team and scientific advisory board on the cutting edge of fibrosis research, and numerous collaborations with leading investigators and institutions in the field of fibrosis around the world, Promedior is positioned to be a leader in the development of new therapies for the treatment of fibrotic disorders and diseases. Promedior is backed by leading institutional healthcare investors including Morgenthaler Ventures, Polaris Venture Partners, HealthCare Ventures and Easton Capital. Learn more about Promedior at www.promedior.com.

Contact: Promedior, Inc.
Dominick Colangelo
Chief Executive Officer
610-560-1435

 

Posted: January 2009

View comments

Hide
(web1)